Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

Table 1 Clinical trials of ASI in suspected minimal residual CRC

Ref	ASI	Stage of patient	Overall Survival	Disease-free Survival	Follow up	Jadad's grades
			No. of events/no. of subjects		(year)
[21]	ATC	Stage II	Con:31 of 109	Con:35 of 109	7.6	B
			Exp:16 of 73	Exp:18 of 73
		Stage III	Con:26 of 44	Con:28 of 44
			Exp:15of 33	Exp:15 of 33
[22]	ATC-BCG	Stage II	Con:21 of 77	Con:29 of 77	5	C
			Exp:14 of 80	Exp:17 of 80
		Stage III	Con:12 of 40	Con:17 of 40
			Exp:16of 44	Exp:20 of 44
[23]	ATV-NDV	Stage I-IV	Con:16 of 25	NO	7	C
			Exp:12of 25
[24]	17-1	Stage III	Con:48 of 76	Con:54 of 76	7	B
	Antibody		Exp:39 of 90	Exp:50 of 90
[25]	ATC	Stage I-IV	Con:146 of 257	NO	7	C
			Exp:135 of 310
[26]	ATC	Stage IV	Con:48 of 50	NO	1	C
			Exp:20 of 42

Abbreviations: Ref, reference; ASI, active specific immunotherapy; Con, control group; Exp, ASI experiment group; ATC, antilogous tumor cells; NDV, newcastle disease virus; No, not done.

ISSN: 1479-5876